Literature DB >> 7106164

Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug.

P E Grebow, J A Treitman, E P Barry, D J Blasucci, S T Portelli, N C Tantillo, R A Vukovich, E S Neiss.   

Abstract

Two formulations of indapamide tablets (2.5 mg) were given as a 5.0 mg dose and the subsequent blood levels were compared to those obtained after administration of a 5.0 mg solution. The study was conducted as a randomized three-way crossover design using healthy male volunteers. The drug was well tolerated by all the subjects involved. The area under the blood concentration versus time curve, extrapolated to infinity was essentially the same for all three formulations (4.2, 4.7, and 4.4 microgram-h/ml). Statistical comparison of the blood levels from the two tablets showed that one tablet had a significantly shorter time of maximum blood concentration (2.3 vs 3.5). Cmax(333ng/ml) and tmax (0.7h) values for the solution were significantly higher than either tablet. The average half-life (beta-phase) for all three formulations was 15 h, while the average systemic clearance was 20 ml/min. Indapamide has a low clearance rate and there was no evidence that the drug undergoes a first-pass effect.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7106164     DOI: 10.1007/BF00548396

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Fluorometric assay for urinary indapamide.

Authors:  P E Grebow; J A Treitman; A K Yeung
Journal:  J Pharm Sci       Date:  1978-08       Impact factor: 3.534

3.  Semiautomated assay for indapamide in biological fluids.

Authors:  P E Grebow; J A Treitman; A K Yeung; M M Johnston
Journal:  J Pharm Sci       Date:  1981-03       Impact factor: 3.534

4.  Evaluation of indapamide in the treatment of hypertension.

Authors:  S N Anavekar; A Ludbrooke; W J Louis; A E Doyle
Journal:  J Cardiovasc Pharmacol       Date:  1979 Jul-Aug       Impact factor: 3.105

5.  Pharmacokinetics of indapamide in dogs.

Authors:  P E Grebow; J A Treitman
Journal:  J Pharm Sci       Date:  1981-12       Impact factor: 3.534

  5 in total
  3 in total

Review 1.  Diuretics. Clinical pharmacology and therapeutic use (Part I).

Authors:  A Lant
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of some newer diuretics.

Authors:  B Beermann; M Grind
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

3.  Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension.

Authors:  M Chaffman; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.